| Target Price | $401.88 |
| Price | $327.63 |
| Potential |
22.66%
register free of charge
|
| Number of Estimates | 23 |
|
23 Analysts have issued a price target Elevance Health 2026 .
The average Elevance Health target price is $401.88.
This is
22.66%
register free of charge
$515.77
57.42%
register free of charge
$299.97
8.44%
register free of charge
|
|
| A rating was issued by 29 analysts: 17 Analysts recommend Elevance Health to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Elevance Health stock has an average upside potential 2026 of
22.66%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 176.81 | 200.17 |
| 3.19% | 13.21% | |
| EBITDA Margin | 5.51% | 5.31% |
| 9.12% | 3.57% | |
| Net Margin | 3.38% | 3.36% |
| 3.21% | 0.66% |
22 Analysts have issued a sales forecast Elevance Health 2025 . The average Elevance Health sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Elevance Health EBITDA forecast 2025. The average Elevance Health EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
26 Elevance Health Analysts have issued a net profit forecast 2025. The average Elevance Health net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 25.68 | 30.27 |
| 1.82% | 17.87% | |
| P/E | 10.82 | |
| EV/Sales | 0.48 |
26 Analysts have issued a Elevance Health forecast for earnings per share. The average Elevance Health EPS is
This results in the following potential growth metrics and future valuations:
Elevance Health...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Mizuho |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Oct 28 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Oct 23 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Oct 22 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Oct 22 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Oct 14 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Oct 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Mizuho:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Oct 28 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Oct 23 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Oct 22 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Oct 22 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Oct 14 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Oct 14 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


